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Astrocytomas, the most common type of gliomas, and especially grade IV glioblastomas are “endowed” with strong proliferation
and invasion potentials, high recurrence rate, and poor patients’ prognosis. Aberrant signaling of AKT-mTOR (mammalian target
of rapamycin) has been implicated in carcinogenesis. This paper is focused on the impact of deregulated AKT-mTOR signaling
components in the clinical outcome and prognosis of human astrocytomas. Current therapeutic targeting of astrocytomas with
AKT-mTOR inhibitors in preclinical and clinical stage is also discussed, including future perspectives regarding the management
of these devastating tumors.
1.Introduction
Gliomas present the commonest type of tumor of the central
nervous system. Based on the World Health Organization
(WHO) criteria, diﬀuse astrocytomas, the most aggressive
type of gliomas, are further classiﬁed into varying degrees
of malignancy ranging from grade II to IV [1]. The life
expectancy of patients diagnosed with a grade IV astro-
cytoma is on average 14 months after diagnosis despite
diﬀerential treatment strategies including surgery, radiation,
and/or chemotherapy.
The development of phosphorylation state-speciﬁc anti-
bodies (PSSAs) has enabled a static determination of protein
phosphorylation in the spatially complex structures of cells
and tissues [2]. What is expected from PSSAs is the ability
to confer a “screenshot” of intracellular signal transduction
pathways, so as to provide important information to the
clinicianregardingprognosis,prediction,and/ortherapy[2].
It is well established that the deregulation of AKT-mTOR
(mammalian target of rapamycin) signaling is involved in
carcinogenesis and plays a major role in the development
of an aggressive phenotype inﬂuencing prognosis and deter-
mining response to therapies. The aim of this paper is to
critically discuss and compose the results of several reports
dealing with the role of activated AKT-mTOR pathway in
human diﬀuse astrocytomas. We will focus on reports that
used PSSAs for the activated form of AKT, mTOR, p70S6K,
S6, and 4E-BP1 and highlight the role of these molecules in
gliomagenesis.
2. The AKT-mTOR Pathway
2.1. A Quick Overview (Figure 1). AKT is one of the most
important downstream targets of PI3K (phosphoinositide
3 -kinase). The AKT-mTOR pathway is initially activated at
the level of cell membrane, and propagation of the activation
signal occurs through PI3K class IA. A variety of signaling
molecules including tyrosine kinase growth factor receptors
(e.g., epidermal growth factor receptor (EGFR), insulin-like
growth factor-1 receptor (IGF-1R)) as well as G-protein-
coupled receptors, cell adhesion molecules, and oncogenes
may lead to PI3K activation [3]. Phosphatidylinositol-
3,4,5-triphosphate (PIP3), PI3K product, binds to 3 -
phosphoinositide-dependent kinase 1 (PDK-1) and AKT
through the pleckstrin homology domains (PH). This allows2 Neurology Research International
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Figure 1: Schematic representation of AKT-mTOR signaling
pathway showing rapamycin inhibition sites in astrocytomas.
the translocation of both proteins to the cell membrane,
followed by their activation [4]. Colocalization of AKT
with PDK1 results in phosphorylation of AKT at Thr308
and its partial activation [5]. In order for AKT to be
fully activated, an additional Ser473 phosphorylation by the
putative kinase PDK2 is required, which is believed to be
mTORC2 (mTOR complex 2) [6]. PI3K is antagonized by
PTEN (phosphatase and tensin homolog deleted on chro-
mosome 10) through dephosphorylation of PIP3, thereby
preventing AKT translocation and subsequent activation of
both AKT and PDK-1. Once activated, AKT moves to the
cytoplasmandnucleus,whereitphosphorylates,activates,or
inhibitsmanydownstreamtargetstoregulatevariouscellular
functions including cell metabolism, protein synthesis, cell
survival/inhibition of apoptosis, and cell cycle progression.
mTOR, a serine/threonine kinase, presents AKT’s most
well-studied downstream substrate. mTOR can be either
directly phosphorylated and activated by AKT or indirectly
activated through phosphorylation and subsequent inac-
tivation of TSC2 (tuberous sclerosis complex 2, known
as tuberin). TSC2 usually inhibits mTOR via Rheb (Ras
homolog enriched in brain), a GTP-binding protein. Phos-
phorylation of TSC2 leading to its inactivation allows Rheb
kept in the GTP-bound state, further inducing increased
mTOR activation [3]. Two complexes of mTOR exist
including the complex of mTORC1, with mTOR binding to
Raptor, and the complex mTORC2, with mTOR binding to
Rictor. Among several functions of mTOR, the regulation
of translation is the best studied in relation to oncogenesis
[7]. Two downstream pathways of mTORC1 involved in
the translation machinery are responsible for ribosome
recruitment to mRNA: phosphorylation and inactivation
of 4E-BP1 (eukaryotic translation initiation factor 4E-
binding protein 1), the repressor of mRNA translation, and
activation of S6K1 (ribosomal S6 kinase 1), the promoter
of mRNA translation [8]. 4E-BP1 phosphorylation (p-4E-
BP1) prevents eIF4E interaction, liberating it to interact with
eIF4G to form the eIF4F complex that enhances the cell’s
overalltranslationalmachinery[9].BecauseeIF4Eistheleast
abundant among the initiation factors, its dissociation from
4E-BPs represents the rate-limiting event for cap-dependent
initiation of translation. Many growth- and proliferation-
related proteins encoded by “weak” mRNAs show great
reliance on the availability of eIF4E [10]. S6K1, which is
phosphorylatedandactivatedbymTORC1onahydrophobic
motif, further phosphorylates S6, the 40S ribosomal protein,
enhancing mRNAs translation with a 5 -TOP (5 -terminal
oligopolypyrimidine). Allribosomalproteinsandelongation
factors are encoded by 5 -TOP [11].
2.2. AKT Protein: A Basic “AKTor” in Human Astrocytomas.
AKT (also known as protein kinase B, PKB) is a ser-
ine/threonine kinase with three isoforms being identiﬁed
in mammalian cells: AKT1 (PKBα), AKT2 (PKBβ), and
AKT3 (PKBγ). They are all encoded by diﬀerent genes with
ubiquitous expression in normal cells and variable levels of
expression among tissues [27]. AKT is a central node of
PI3K signaling pathway, with crosstalk and feedback loops
inﬂuencing its regulation. Altered expression of AKT has
been associated with carcinogenesis [28].
Several studies [12–26] have investigated the clinical and
prognostic signiﬁcance of AKT and its activated form (phos-
phorylated AKT, p-AKT) in human astrocytomas (Table 1),
without discrimination between the nuclear and cytoplasmic
localization of this molecule apart of a few reports. The
subcellularlocalizationofp-AKTis,however,veryimportant
sincecurrentdataindicatediﬀerentiallyshapedsignalingina
spatially restricted way [13]. Interestingly, increased levels of
nuclear p-AKT expression were correlated with higher levels
of cytoplasmic immunostaining [13, 15]. These correlations
between nuclear and cytoplasmic immunoexpression, along
with the concurrent nuclear and cytoplasmic localization
of p-AKT, are compatible with the dual regulatory role of
gene expression targeting proteins in both cytoplasmic and
nuclear level. It is worthy of note the ﬁndings of the study
of Annovazzi et al. [18] showing that the immunostaining of
p-AKT was nuclear in low-grade gliomas and cytoplasmic in
high-grade gliomas. The reason for this disparity is unclear
despite the explanation given by the latter group supporting
that the prevailing nuclear localization in low-grade gliomas,
where AKT expression is infrequent, could mean that
the regulatory mechanism is diﬀerent in comparison with
tumors with cytoplasmic localization.
All reports dealing with diﬀerent grades of human astro-
cytomas, except one, showed that increased total, nuclear,Neurology Research International 3
Table 1: Summary of reports investigating the role of AKT and p-AKT in astrocytomas.
Report (number
of cases and
grades)
Antibody used Immunostaining
percentage
Correlations with
clinicopathological
features
Other correlations Survival analysis
Yang et al. [12]
(96 patients: 16
grade II, 35 III,
and 45 IV)
Rabbit monoclonal
anti-p-AKT
(Ser473) ab (CST),
at a concentration of
1.5Ig/mL (IHC)
92.7% (89/96)
showed nuclear and
cytoplasmic staining
p-AKT with
(i) higher grade
(ii) lower KPS
score
—
(i) p-AKT associated
with a worse
prognosis
(ii) Multivariate
analysis: p-AKT as an
independent
prognostic factor
Saetta et al. [13]
(82 patients: 20
grade II, 14 III,
and 48 IV)
Rabbit polyclonal
anti-p-AKT1/2/3 ab
(SCB), diluted
1:250 (IHC)
p-AKT:
(i) nuclear 93.05%
(67/72)
(ii) cytoplasmic
59.72% (43/72)
(i) Nuclear and
cytoplasmic
p-AKT with tumor
grade
(ii) Cytoplasmic
p-AKT with
patients’ age
(i) Nuclear p-AKT
with cytoplasmic
p-AKT
(ii) Nuclear and
cytoplasmic p-AKT
with nuclear and
cytoplasmic p-ERK
(iii) Nuclear p-AKT
with VEGF and MVD
Multivariate analysis:
cytoplasmic p-AKT as
independent
predictor of survival
(higher survival
probability)
Li et al. [14]( 8 7
patients: 27 grade
I-II, 24 III, and 36
IV)
Rabbit monoclonal
anti-p-AKT ab (EP),
diluted 1:200 (IHC)
(i) 72.4% (63/87)
showed nuclear
and/or cytoplasmic
staining
(ii) 36.1% of grade IV
showed strong
expression
High p-AKT levels
with tumor grade ——
El-Habr et al.
[15] (71 patients:
7 grade II, 5 III,
and 59 IV)
Rabbit polyclonal
anti-p-AKT1/2/3 ab
(SCB), diluted
1:250 (IHC)
p-AKT:
(i) nuclear 97%
(22/24)
(i) cytoplasmic 100%
Cytoplasmic
p-AKT with tumor
grade
Nuclear p-AKT with
cytoplasmic p-AKT —
Wang and Kang
[16] (48 patients:
16 grade II, 23 III,
and 9 IV)
(i) Mouse
monoclonal
anti-AKT2 ab SCB,
diluted 1:100 for
IHC and 1:500 for
WB
(ii) p-AKT
(information not
provided) diluted
1:500 for WB
64.6% (31/48)
showed cytoplasmic
AKT2 staining
AKT2 and p-AKT
with tumor grade AKT2 with Ki-67 —
Suzuki et al. [17]
(64 patients grade
IV)
Rabbit polyclonal
anti-p-AKT
(Ser473) ab (CST),
diluted 1:200 (IHC)
(i) 68.8% (44/64)
(ii) 29.7% (19/64)
had greater than 50%
p-AKT positivity
——
(i) p-AKT positive,
lower survival rate
than p-AKT negative
(ii) Multivariate
analysis: higher
expression of p-AKT
with poor prognosis
Annovazzi et al.
[18] (54 patients:
10 grade II, 10 III,
and 34 IV)
(i) Mouse
monoclonal
anti-p-AKT
(Ser473) ab (CST),
diluted 1:100 (IHC)
(ii) Rabbit
monoclonal
anti-p-AKT
(Ser473) ab (CST),
diluted 1:1000
(WB)
(i) 0%, 50%, and
56.6% in grade II, III,
and IV, respectively
(ii) Nuclear in grade
II and III but mainly
cytoplasmic in grade
IV
p-AKT with tumor
grade
p-AKT with
(i) EGFR
ampliﬁcation
(ii) p-mTOR
No signiﬁcant
correlation4 Neurology Research International
Table 1: Continued.
Report (number
of cases and
grades)
Antibody used Immunostaining
percentage
Correlations with
clinicopathological
features
Other correlations Survival analysis
Matsutani et al.
[19] (24 patients)
Mouse monoclonal
anti-AKT1 (B-1) ab
(SCB) (IHC)
58.3% (14/24),
cytoplasmic staining —
(i)Positive AKT with
tumor recurrences
(ii) Overexpressed
AKT with invasive
recurrence into
surrounding brain
AKT overexpression
with:
(i) shorter OS
(ii) PFS
Multivariate analysis:
AKT overexpression
as a signiﬁcant
prognostic factor for
shorter PFS
Hlobilkova et al.
[20] (89 patients:
42 grade I-II and
47 grade III-IV)
Mouse monoclonal
anti-p-AKT
(Ser473) ab (IHC)
86% of low grade and
in 79% of high grade
No correlation
with grade
p-AKT with EGFR
activation —
Mizoguchi et al.
[21] (82 patients:
27 grade III and
55 IV)
Rabbit polyclonal
anti-p-AKT
(Ser473) ab (CST),
diluted 1:100 (IHC)
(i) 78.2% of
glioblastomas (43/55)
positive nuclear
and/or cytoplasmic
(ii) 18.5% of
anaplastic
astrocytomas (5/27)
positive nuclear
and/or cytoplasmic
p-AKT with tumor
grade
p-AKT with
(i) EGFRvIII
(ii) EGFRwt
(iii) p-STAT3
p-AKT marginally
predictive of worse
prognosis
Pelloski et al. [22]
(268 grade IV)
Rabbit polyclonal
anti-p-AKT
(Ser473) ab (CST),
diluted 1:300 (IHC)
Not provided —
p-AKT with
(i) p-ERK
(ii) p-p70S6K
(iii) p-mTOR
(iv) YKL-40
No signiﬁcant
correlation
Riemenschneider
et al. [23]( 2 9
grade IV)
Rabbit monoclonal
anti-p-AKT
(Ser473) ab (CST),
diluted 1:50 (IHC)
Not provided —
p-AKT with
(i) p-TSC2
(ii) p-S6K
(iii) p-S6
—
Wang et al. [24]
(128 patients: 9
grade II, 49 III,
and 70 IV)
Rabbit polyclonal
anti-p-AKT
(Ser473) ab (CST),
diluted 1:50 (IHC)
p-AKT in:
(i) 84% (59/70) grade
IV
(ii) 44% (20/46)
grade III
(iii) 22% (2/9) grade
II
p-AKT with tumor
grade
p-AKT with activated
NFκB —
Chakravarti et al.
[25]( 1 1g r a d eI I ,
13 III, and 56 IV)
p-AKT (Thr308) ab
(CST) (WB)
66% (50/92) of grade
IV
p-AKT with tumor
grade
p-AKT with
(i) p-PI3K
(ii) p-p70S6K
(iii) inversely with
cCas3
p-AKT with
(i) adverse outcome
(ii) reduced time to
death
Choe et al. [26]
(45 grade IV)
Rabbit polyclonal
anti-p-AKT
(Ser473) ab (CST),
diluted 1:50 (IHC)
Not provided —
p-AKT with
(i) PTEN protein loss
(ii) p-FKHR
(iii) p-S6
(iv) p-mTOR
—
ab:antibody,cCas3:cleavedcaspase3,CST:CellSignalingTechnology(Beverly,MA),EP:Epitomics(CA,USA),IHC:immunohistochemistry,KPS:Karnofsky
Performance Status, MVD: microvessel density, OS: overall survival, p-ERK: phosphorylated extracellular-signal-regulated kinase, PFS: progression-free
survival, SCB: Santa Cruz Biotechnology, VEGF: vascular endothelial growth factor, WB: Western blot.
and/or cytoplasmic AKT and p-AKT correlated with tumor
histological grade (Table 1) indicating that activation of
AKT participates in astrocytic tumor progression. On the
contrary, Hlobilkova et al. [20] found the same propor-
tions of p-AKT expression between low- and high-grade
astrocytomas, suggesting that its activation is a starting
event in gliomagenesis. Yang et al. [12] showed a signiﬁcant
correlation of p-AKT expression with KPS (Karnofsky
Performance Status) score, whereas a signiﬁcant association
between cytoplasmic p-AKT expression and patients’ ageNeurology Research International 5
was denoted by Saetta et al. [13]. Also, from the same
study [13], correlations of nuclear p-AKT expression with
VEGF (vascular endothelial growth factor) and microvessel
density were observed, which implicate p-AKT as major
component of angiogenesis in astrocytic gliomas. Matsutani
et al. [19] found that patients positive for AKT with residual
tumors postoperatively exhibited tumor recurrences, and
invasive recurrence into surrounding brain was present only
in tumors overexpressing AKT.
Two independent studies [13, 22], unlike Mizoguchi et
al. [21]a n dC h o ee ta l .[ 26], observed that p-AKT ex-
pression correlates to expression of p-ERK in gliomas. This
correlation can be explained by the simultaneous activation
of these parallel pathways by common receptor tyrosine
kinases (e.g., EGFR) acting upstream. This can be further
supported by the correlation of p-AKT activation with EGFR
gene ampliﬁcation and with progression from anaplastic
astrocytomas to glioblastoma [18, 21]. More speciﬁcally, the
immunostaining of wild type-EGFR (EGFRwt) [18, 21]a n d
mutant EGFR (EGFRvIII) [21] correlated with activation of
AKT. Also, from the latter report [21], a strong association
between p-AKT and expression of p-STAT3 was denoted,
whereas the statistical analysis of two independent studies
[23, 24] failed to conﬁrm such a relation. On the other
hand, the immunohistochemical data from the microarray
study of Wang et al. [24] showed an important correlation
between p-AKT and activated NF-κB, suggesting that AKT
activation may lead to NF-κBa c t i v a t i o ni nd i ﬀuse astrocy-
tomas. The ﬁnding of Chakravarti et al. [25] that shows an
inverse association of p-AKT levels with cleaved caspase 3
(an apoptotic marker) levels indicates that PI3K members
may act towards suppression of apoptosis, suggesting a
possible explanatory mechanism by which the PI3K pathway
may enhance resistance to radiation therapy in grade IV
astrocytomas. Such a ﬁnding did not emerge from the study
of Annovazzi et al. [18] probably due to technical reasons.
Since the expression status of mutant IDH1 (isocitrate
dehydrogenase 1) has been recently proposed as a prognostic
factorinastrocytictumors[29],Saettaetal.[13]includedthe
IDH1-R132H antibody in their immunohistochemical anal-
ysis, which is a surrogate marker of the IDH1 mutant, in a
subset of cases in order to evaluate any potential relationship
with p-AKT, but the expression of the former was not
related neither to nuclear nor to cytoplasmic p-AKT. Also,
the same group in a latter study [30] (see below) examined
any possible correlation of IDH1-R132H expression with
the activated forms of mTOR, p70S6K, and 4E-BP1. All
three proteins were found to be unrelated to IDH1-R132H
expression.
The relationships of p-AKT with p-mTOR and its down-
stream molecules will be discussed in next sections. From
some reports, several correlations of p-AKT and its upstream
regulators have emerged. In vitro experiments have shown
that addition of YKL-40 protein to cells of connective
tissue resulted in increased cell proliferation through AKT
activation and MAPK pathways, nominating YKL-40 as a
potential regulator of these signaling pathways, since its
secreted form is the product of one of the most expressed
genes in glioblastoma with prognostic potential for these
tumors [22]. YKL-40 expression was marginally correlated
with expression of p-AKT in the study of Pelloski et al. [22],
but,fromthesamestudy,nocorrelationwasobservedamong
expression of p-AKT and PTEN. On the contrary, Choe et
al. [26] found a strong inverse correlation between AKT
activationandPTENloss,whichremainedsigniﬁcantduring
multivariate analysis. Also, from the same report [26], a
statistical correlation between p-AKT and p-FKHR emerged
and was maintained as an independent association during
multivariate analysis. Since AKT is an important mediator
of PI3K, a signiﬁcant association among the activation states
of these two proteins was expected [25].
The prognostic importance of AKT or p-AKT in astro-
cytic tumors is controversial based on current literature. The
study of Matsutani et al. [19] found overexpression of AKT
to be signiﬁcantly associated with progression-free survival
(PFS) and shorter overall survival (OS). In other reports, p-
AKT expression was predictive of worse prognosis [12, 17,
21, 25]. Chakravarti et al. [25] showed elevated expression
levels of p-AKT to be signiﬁcantly associated with reduced
time to death in the entire cohort, but such a relation did
not remain signiﬁcant during multivariate survival analysis.
They then examined the prognostic signiﬁcance of p-AKT
only in patients diagnosed with a grade IV astrocytoma
treated by surgery combined with postoperative radiation
and showed a correlation of p-AKT expression with adverse
outcome, suggesting an important role of this pathway
in radiation resistance. Yang et al. [12] found also that
p-AKT expression was statistically associated with worse
prognosis, but, unlike Chakravarti et al. [25], in multivariate
survival analysis, p-AKT emerged as an independent factor
of prognosis. In the same context, the report of Suzuki et al.
[17] showed that rate of survival for p-AKT positive tumor
patients was lower than that of p-AKT negative tumors,
whereas multivariate survival analysis nominated p-AKT as
a strong independent prognostic factor. During univariate
survival analysis of Saetta et al. [13], p-AKT expression did
not correlate with survival, whereas multivariate analysis
revealed cytoplasmic p-AKT expression as an independent
prognostic factor,implying ahighersurvivalprobability. The
latter ﬁnding is not one of a kind, since it is in accordance
with current observations in lung and ovarian tumors [31,
32]. Finally, in two independent reports [18, 22], p-AKT
expression failed to attain prognostic signiﬁcance in gliomas.
2.3. The Role of mTOR Protein in Astrocytomas. The mTOR
proteins belong to the PIKK (phosphoinositide 3-kinase-
related kinase) family, transmitting signals associated with
cellular growth, proliferation, and stress responses [33].
mTOR is a large protein of ∼300kDa Mwt with a COOH-
terminal catalytic domain homologous to PI3K, functioning
exclusively as a protein serine/threonine kinase [34].
Some reports [14, 18, 22, 23, 26, 30]h a v ei n v e s t i g a t e d
the clinical and prognostic signiﬁcance of activated mTOR
(phosphorylated mTOR, p-mTOR) in human astrocytomas.
Table 2 summarizes the important ﬁndings of these reports.
In the report of Korkolopoulou et al. [30], mTOR was
seen predominantly in the cytoplasm/cell membrane but6 Neurology Research International
Table 2: Summary of reports investigating the role of mTOR activation in astrocytomas.
Report (number
of cases and
grades)
Antibody used Immunostaining
percentage
Correlations with
clinicopathological
features
Other correlations Survival analysis
Korkolopoulou
et al. [30] (111
patients: 25
grade II, 15 III,
and 71 IV)
Rabbit monoclonal
anti-p-mTOR
(Ser2448) ab
(CST), diluted
1:50forIHCand
1:1.000 (WB)
(i) 84.7% (94/111)
cytoplas-
mic/membranous
(ii) 2.7% (3/111)
nuclear
Gade III and IV
marginally higher
p-mTOR expression
than grade II
p-mTOR with
(i) nuclear and
cytoplasmic p-AKT
(ii) p-p70S6K
(iii) p-4E-BP1
(iv) VEGF
p-mTOR with worse
DFS
Li et al. [14]( 8 7
patients: 27
grade I-II, 24 III,
and 36 IV)
Rabbit monoclonal
anti-p-mTOR
(Ser2448) ab (EP),
diluted 1:100
(IHC)
(i) 74.7% (65/87)
nuclear and/or
cytoplasmic
(ii) 44.4% of grade IV
strong expression
p-mTOR with tumor
grade ——
Annovazzi et al.
[18] (54 patients:
10 grade II, 10
III, and 34 IV)
Rabbit polyclonal
anti-p-mTOR
(Ser2448) ab
(CST), diluted
1:75(IHC)
0%, 70%, and 81.8%
nuclear in grade II,
III, and IV,
respectively
p-mTOR with tumor
grade
p-mTOR with
(i) p-AKT
(ii) inversely Beclin 1
No signiﬁcant
correlation
Pelloski et al.
[22] (268 grade
IV)
Anti-p-mTOR
(Ser2448) ab
(CST), diluted
1:100 (IHC)
Not provided —
p-mTOR with
(i) p-ERK
(ii) p-p70S6K
(iii) p-AKT
(iv) PTEN
(v) YKL-40
(i) p-mTOR with
shorter OS
(ii) Multivariate
analysis: not retained
as an independent
prognostic factor
Riemenschneider
et al. [23]( 2 9
grade IV)
Rabbit polyclonal
anti-p-mTOR
(Ser2448) ab
(CST), diluted
1:75(IHC)
Not provided — No signiﬁcant
correlation —
Choe et al. [26]
(45 grade IV)
p-mTOR
(Ser2481) ab
(CST), diluted
1:50(IHC)
Not provided —
p-mTOR with
(i) p-AKT
(ii) p-S6
(iii) EGFRvIII
—
ab: antibody, CST: Cell Signaling Technology (Beverly, MA), DFS: disease-free survival, EP: Epitomics (CA, USA), IHC: immunohistochemistry, OS: overall
survival, p-ERK: phosphorylated extracellular-signal-regulated kinase, VEGF: vascular endothelial growth factor, WB: Western blot.
also occasionally in the nucleus, suggesting that this nuclear
importofmTORmayhaveanimportantroleinactivatingits
cytoplasmicsignaling.Ontheotherhand,Lietal.[14]found
that the immunostaining of p-mTOR was both nuclear
and cytoplasmic, whereas Annovazzi et al. [18]o b s e r v e d
a nuclear immunostaining. The reason for the disparity in
mTOR immunostaining may be due to the diﬀerence in the
antibodies used and requires further investigation.
It is worthy of note that 3 independent reports [14, 18,
30] dealing with diﬀerent grade of astrocytomas denoted
a correlation of p-mTOR expression with tumor grade.
These ﬁndings imply that activation of mTOR may be a late
event during gliomagenesis, facilitating the acquisition of a
malignant phenotype.
An association between VEGF and cytoplasmic p-AKT
levels in astrocytic tumors was discussed previously in
Section 2.2 [13] .T h es a m eg r o u p[ 30] denoted that this
relationshipalsoappliestop-mTORanditstargetproteinsp-
4E-BP1 and p-p70S6K, which was illustrated in their similar
distribution in perinecrotic areas of glioblastomas (Tables 3
and 4). Their ﬁndings are supported by recent data clearly
placing HIF-1a the driving force of VEGF upregulation
and angiogenesis under hypoxic conditions downstream of
mTOR [37], as well as from in vitro experiments where
decreased VEGF levels with suppression of angiogenic phe-
notype followed mTOR inhibition or enhanced translation
of VEGF mRNA followed hypoxic activation of 4E-BP1 and
eIF4E [30]; Beclin 1, expression of which decreases with
malignancy, was inversely correlated with p-mTOR [18].
Since AKT and mTOR proteins interact with and activate
each other as discussed in Section 2.1, it is expected the
activated forms of these two proteins to be correlated
together. Indeed, several reports have denoted a correlation
of these two proteins [18, 22, 26, 30]. Choe et al. [26]
found a strong correlation of p-AKT and p-mTOR in
univariate analysis, but, in multivariate, this association did
not reach signiﬁcance, concluding that additional inputs
(e.g., nutrients, amino acids, cellular ATP, and phosphatidic
acid) to mTOR activation are involved, some of which may
be associated with other parts of the signaling pathway. Only
one report [23] did not observe association between p-AKT
and p-mTOR suggesting that multiple AKT-independentNeurology Research International 7
Table 3: Summary of reports investigating the role of p70S6K and S6 activation in astrocytomas.
Report (number
of cases and
grades)
Antibody used Immunostaining
percentage
Correlations with
clinicopathological
features
Other correlations Survival analysis
Korkolopoulou
et al. [30] (111
patients: 25
grade II, 15 III,
and 71 IV)
Rabbit polyclonal
anti-p-p70S6K
(Thr421/Ser424) ab
(speciﬁc for p70
subunit) (SCB),
diluted 1:250 for
IHC and 1:200 for
WB
99.1% (99/111)
showed nuclear
staining
No signiﬁcant
correlation
p-p70S6K with
(i) cytoplasmic p-AKT
(ii) p-mTOR
(marginal)
(iii) VEGF
No signiﬁcant
correlation
Yang et al. [12]
(96 patients: 16
grade II, 35 III,
and 45 IV)
Rabbit polyclonal
anti-p-S6
(Ser235/236) ab
(CST), at a
concentration of
0.125Ig/mL (IHC)
82.3% (79/96)
cytoplasmic
p-S6 with
(i) tumor grade
(ii) lower KPS
score
—
(i) p-S6 with worse
prognosis
(ii) Multivariate
analysis: p-S6 as an
independent
prognostic factor
Li et al. [14]( 8 7
patients: 27
grade I-II, 24 III,
and 36 IV)
Rabbit monoclonal
anti-p-p70S6K
(Thr389) ab (EP),
diluted 1:50 (IHC)
(i) 72.4% (63/87)
nuclear and/or
cytoplasmic
(ii) 41.7% of grade IV
showed strong
expression
p-p70S6K with
tumor grade ——
McBride et al.
[35] (45 patients:
22 astrocytomas
grade II)
(i) Rabbit polyclonal
anti-p-S6
(Ser235/236) ab
(SCT), diluted
1:200 (IHC)
(ii) Rabbit
polyclonal anti-p-S6
(Ser240/244) ab
(CST), diluted
1:200 (IHC)
(i) p-S6 (Ser235/236):
76% (29/38)
(ii) p-S6
(Ser240/244): 76%
(29/38)
—
p-S6 (Ser235/236)
with
(i) p-PRAS40
(ii) p-S6 (Ser240/244)
p-S6 (Ser240/244)
with
(iii) PTEN
methylation
(iv) inversely PTEN
expression
(i) p-S6 (Ser235/236)
with OS
(ii) p-S6 (Ser240/244)
with OS
Annovazzi et al.
[18] (54 patients:
10 grade II, 10
III, and 34 IV)
Rabbit polyclonal
anti-p-S6
(Ser240/244) ab
(CST), diluted
1:100 for IHC. Not
provided for WB
(i) 0%, 30%, and
82.3% in grade II, III,
and IV, respectively
(ii) Nuclear in grade
II and III but mainly
cytoplasmic in grade
IV
p-S6 with tumor
grade
p-S6 IHC with
(i) p-S6 WB
(ii) Ki-67
(iii) inversely with
Beclin 1
No signiﬁcant
correlation
Ermoian et al.
[36] (71 patients:
28 grade II, 17
III, and 26 IV
Anti-p-S6 ab (CST) Not provided p-S6 unrelated to
tumor grade
No signiﬁcant
correlation
No signiﬁcant
correlation
Pelloski et al.
[22] (268 grade
IV)
Anti p-p70S6K ab
(CST), diluted
1:1000 (WB)
Not provided —
p-p70S6K with
(i) p-ERK
(ii) p-mTOR
(iii) p-AKT
(iv) PTEN
(v) YKL-40
(i) p-p70S6K with
shorter OS
(ii) Multivariate
analysis: not retained
as an independent
prognostic factor
Riemenschneider
et al. [23]( 2 9
grade IV)
(i) Mouse
monoclonal
anti-p-p70S6K
(Thr389) ab (CST),
diluted 1:200 (IHC)
(ii)Rabbit
monoclonal
anti-p-S6
(Ser235/236) ab
(CST), diluted
1:200 (IHC)
Not provided —
(i) p-p70S6K
with p-AKT
(ii) p-S6 with p-AKT
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Table 3: Continued.
Report (number
of cases and
grades)
Antibody used Immunostaining
percentage
Correlations with
clinicopathological
features
Other correlations Survival analysis
Ckakravarti et al.
[25]( 1 1g r a d eI I ,
13 III, and 56 IV)
Anti-p-p70S6K
(Thr389) ab (CST),
diluted 1:50 (WB)
39.1% (36/92) of
grade IV
p-p70S6K with
tumor grade
p-p70S6K with
(i) p-PI3K
(ii) p-AKT
(iii) inversely cCas3
p-p70S6K with
(i) adverse outcome
(ii) reduced time to
death
Multivariate analysis:
p-p70S6K as an
independent
prognostic factor
Choe et al. [26]
(45 grade IV)
Anti p-S6
(Ser235/236) ab
(CST), diluted 1:50
(IHC)
Not provided —
p- S6 with
(i) EGFRwt
(ii) EGFRvIII
(iii) p-mTOR
(iv) p-ERK
—
ab:antibody,cCas3:cleavedcaspase3,CST:CellSignalingTechnology(Beverly,MA),EP:Epitomics(CA,USA),IHC:immunohistochemistry,KPS:Karnofsky
Performance Status, OS: overall survival, p-ERK: phosphorylated extracellular-signal-regulated kinase, SCB: Santa Cruz Biotechnology, VEGF: vascular
endothelial growth factor, WB: Western blot.
signaling pathways on mTOR regulation could be involved.
Pelloski et al. [22], unlike Korkolopoulou et al. [30], showed
a strong p-mTOR correlation with p-ERK, which could be
explained by the simultaneous stimulation of these parallel
pathways by EGFR, the expression of which was correlated
with both proteins in the analysis of Choe et al. [26]. Pelloski
et al. [22], also, found a correlation of p-mTOR with YKL-40
(see Section 2.2) and PTEN expression. The latter ﬁnding is
in accordance with previous data of a relationship between
high PTEN expression and AKT activation [22]. The con-
tradictory ﬁndings in the literature suggest a tumor speciﬁc
relationship between PTEN expression and activation of the
AKT pathway and this should be better assessed by alterna-
tive methodology than immunohistochemical analysis.
As mentioned above, the most important eﬀectors of
mTORkinaseintheregulationoftranslationare4E-BP1and
p70S6K,S6ribosomalprotein,beingthemajoreﬀectorofthe
latter. In this context, Choe et al. [26] found an association
between p-mTOR and p-S6, whereas Pelloski et al. [22]
denoted a strong association of the former protein with p-
p70S6K. Korkolopoulou et al. [30] found also correlations
of p-mTOR with p-4E-BP1 and p-p70S6K, the former of
marginal signiﬁcance, but, despite these interrelationships,
the three proteins were topographically distinct, since only
p-mTOR was found in pseudopalisading perinecrotic cells
in glioblastomas. This ﬁnding is one of a kind and could
attribute a functional link with tumor hypoxia, conﬁrmed by
in vitro data indicating upregulation of mTOR by hypoxia
inducible factor-1a (HIF-1a) [37].
Regarding the prognostic signiﬁcance of activated
mTOR, few reports [18, 22, 30] have investigated the in-
ﬂuence of p-mTOR on patients’ survival. From the survival
analysis of Annovazzi et al. [18], no signiﬁcant correlations
ofp-mTORwithpatients’survivalemerged.Onthecontrary,
Pelloski et al. [22] and Korkolopoulou et al. [30] found that
p-mTOR expression was correlated with short OS and free
of disease survival, respectively, but such a relation did not
remain signiﬁcant during multivariate survival analysis.
2.4. Implication of p70S6K and Its Major Eﬀector S6 Protein in
Astrocytomas. There are two isoforms of S6K1 (cytoplasmic
p70S6K1 and nuclear p85S6K1) present in mammals, pro-
duced by alternative splicing from the same transcript [38].
The large isoform, p85S6K1, is composed of an N-terminal
23-aa long, which directs p85S6K1 to the nucleus. On the
contrary, the short form, p70S6K1, is mainly located in
the cytoplasm. Current data indicate a similar regulation of
p85S6K1 and p70S6K1. Initial mapping of the main residues
for p70S6K1 activation was to T229 (of activation loop) and
T389 (of the hydrophobic motif) and subsequently to S371
of the linker domain [39].
Table 3 shows the reports dealing with the signiﬁcance
of p70S6K in human astrocytomas. p70S6K is a nuclear
cytoplasmic shuttling protein, activated in the nucleus by
mTOR and relocalized in the cytoplasm after mRNA transla-
tion initiation [40]. Thus, it is not surprising that p-p70S6K
has been reportedly seen in the cytoplasm and/or in the
nucleus [14, 30]. Two independent reports [14, 25]d e n o t e d
a correlation of p-p70S6K with tumor grade suggesting
that the activation of this protein takes place later during
gliomagenesis. On the contrary, Korkolopoulou et al. [30]
denoted that p70S6K activation may take place at an earlier
stage of the neoplastic process, since no diﬀerence existed
between low- and high-grade cases.
The latter group [30] observed a correlation of cytoplas-
mic p-AKT with p-p70S6K. Interestingly, in multidimen-
sional analysis in glioblastomas, p-p70S6K, but not with p-
mTOR, clustered together with p-AKT implying that the
downstream eﬀect of p-AKT is primarily conveyed by S6K
signaling through TSC2 [23]. The same correlation between
p-AKT and p-p70S6K was denoted by 3 diﬀerent groups [22,
23, 25]. Since p70S6K is an important downstream mediatorNeurology Research International 9
Table 4: Summary of reports investigating the role of phosphorylated 4E-BP1 in astrocytomas.
Report (number
of cases and
grades)
Antibody used Immunostaining
percentage
Correlations with
clinicopathological
features
Other correlations Survival analysis
Korkolopoulou
et al. [30] (111
patients: 25
grade II, 15 III,
and 71 IV)
Rabbit polyclonal
anti-p-4E-
BP1/2/3 (Ser36)
ab (SCB), diluted
1:50forIHCand
1:200 for WB
82.4% (61/74)
nuclear
p-4E-BP1 with
tumor grade
p-4E-BP1 with
(i) nuclear p-AKT
(ii) cytoplasmic
p-ERK
(iii) p-mTOR
(iv) VEGF
(i) p-4E-BP1 adversely
aﬀe c t e ds u r v i v a li nt h e
entire cohort and
marginally in glioblastomas
(ii) Multivariate analysis:
p-4E-BP1 as an
independent predictor of
survival in the entire cohort
as well as in glioblastomas
Ermoian et al.
[36] (71 patients:
28 grade II, 17
III, and 26 IV
Anti-p-4E-BP1 ab
(CST) (WB) Not provided p-4E-BP1 unrelated
to tumor grade
p-4E-BP1 with
p-AKT No signiﬁcant correlation
Riemenschneider
et al. [23]( 2 9
grade IV)
Rabbit polyclonal
anti-p-4E-BP1
(Ser65) ab (CST),
diluted 1:50
(IHC)
Not provided — No signiﬁcant
correlation —
ab: antibody,CST:Cell SignalingTechnology(Beverly,MA), IHC:immunohistochemistry,p-ERK: phosphorylated extracellular-signal-regulated kinase, SCB:
Santa Cruz Biotechnology, VEGF: vascular endothelial growth factor, WB: Western blot.
of PI3K, a signiﬁcant correlation among the activation
states of both proteins is expected and further predicted
by preclinical models. In accordance, p-PI3K levels and p-
p70S6K were correlated in the study by Chakravarti et al.
[25]. Regarding YKL-40 as discussed in Section 2.2 and
2.3, its expression correlated signiﬁcantly with p-p70S6K
[22]. The same report denoted a strong correlation of the
latter with p-ERK; since the activation of AKT was inversely
associated with cleaved caspase 3, it was expected that the
same correlation will occur between p-p70S6K and the latter,
which was found by Chakravarti et al. [25], suggesting
an implication of activated p70S6K in the suppression of
apoptosis.
Pelloski et al. [22] found that p-p70S6K was associated
with reduced overall survival time on univariate but not
in multivariate analysis. A previous study [25] showed this
marker to be signiﬁcantly correlated to survival on both
analysis types. This can be explained statistically since the
percentage of p-p70S6K-negative cases in the former study
(6%) was lower than that in the latter study (44%) or
becausePelloskietal.[22]included,intheirstudy,additional
markers (namely, YKL-40 and p-ERK) with more dominant
molecular eﬀects within tumor cells. Finally, the survival
analysis of Korkolopoulou et al. [30] did not reveal any
association of p-p70S6K with patients’ survival.
The 40S ribosomal subunit protein S6 is the ﬁrst
identiﬁed and the most well-studied substrate of S6K1. Its
phosphorylation has been found to correlate with increased
protein synthesis. After stimulation, S6K1 phosphorylates S6
on ﬁve serine residues (S235, S236, S240, S244, and S247)
within the C-terminus [38].
Table 3 summarizes the ﬁndings of several reports dis-
cussing the role of activated S6 (phosphorylated S6, p-S6) in
human astrocytomas. Yang et al. [12]d e n o t e dac y t o p l a s m i c
immunostaining for p-S6, whereas Annovazzi et al. [18]
found that grade II had diﬀerent immunostaining for p-S6
than grade III and IV (nuclear for grade II and III, and
cytoplasmic for grade IV). Similar ﬁnding emerged for p-
AKT in the same report and was discussed in Section 2.2.
Also, noteworthy is the ﬁndings of McBride et al. [35]w h o
used two diﬀerent antibodies for the activated form of S6
(Table 3). Both antibodies showed the same percentage of
immunostaining, and their expressions were strongly corre-
lated, which served as a good internal validation for their
IHC (immunohistochemistry) protocol. Also, Annovazzi et
al. [18] validated their IHC by WB (Western blot) analysis
and found a strong correlation between the ﬁndings of both
techniques; a signiﬁcant correlation of p-S6 expression with
tumor grade was denoted by 2 diﬀerent groups [12, 18],
whereas Ermoian et al. [36] did not ﬁnd such a relation;
lower KPS was correlated with p-S6 [12].
A protein-positioned downstream of PTEN, namely,
PRAS40,doesnotinhibitthemTORpathwayinitsphospho-
rylated form (discussed in Section 2.1), and it can therefore
beassumedthatuponactivationofthemTORpathway,these
proteinsarelinkedandcorrelateintermsofphosphorylation
status. In accordance, McBride et al. [35] showed association
of S6 and PRAS40 phosphorylation along with PTEN
methylation. In addition, S6 phosphorylation and PTEN
expression were negatively correlated. In the same context,
Riemenschneider et al. [23] found a strong correlation
between p-AKT and p-S6. Finally, Annovazzi et al. [18]10 Neurology Research International
found a strong positive correlation of p-S6 with Ki67 and
negative with Beclin 1 (see Section 2.3).
McBride et al. [35] performed two diﬀerent survival
analyses for their cohort, one with the anti-p-S6 antibody
for the 235/236 epitope and one for the epitope 240/244.
In both cases, an inverse correlation between OS and phos-
phorylation of S6 was denoted. In the same context, Yang et
al. [12] found a strong correlation between p-S6 expression
and worse prognosis, which in multivariate survival analysis
emerged as an independent prognostic factor. On the
contrary, the survival analysis of Annovazzi et al. [18]a n d
Ermoianetal.[36]didnotrevealanycorrelationofp-S6with
patients’ survival.
2.5. 4E-BP1 Protein: The Less Studied in the Pathogenesis of
Astrocytomas. 4E-BP1 (also known as PHAS-1) is a trans-
lation repressor protein and one of the main eﬀectors of
mTOR in the PI3K/AKT signaling pathway that integrates
signals from extracellular stimuli, amino acid availability,
and oxygen and energy status of the cells. 4E-BPs contain a
TOS (TOR signaling) motif that binds the mTORC1, which
controls the activity of 4E-BP1 [41]. mTORC1 activation
leadsto4E-BP1phosphorylationatThr36,Thr45,Ser64,and
Thr69 sites and 4E-BP1 release from eIF4E [41].
Table 4 summarizes the important ﬁndings of the few
reports dealing with the role of activated 4E-BP1 (p-4E-BP1)
inhumanastrocytomas.InthereportofKorkolopoulouetal.
[30], the immunostaining of p-4E-BP1 was nuclear (nuclear
cytoplasmic shuttling protein). Although the mechanisms
of the nuclear localization of p-4E-BP1 have not been
clariﬁed, there is current evidence that eIF4E functions as
a nuclear regulator of several RNAs exportation implicated
in proliferation and cell growth [42]. Also, Korkolopoulou
et al. [30] showed that p-4E-BP1 expression levels increased
with grade, whereas, in the report of Ermoian et al. [36],
no correlation was elicited between p-4E-BP1 mRNA or
protein levels (as measured using immunoblotting) and
glioma grade.
p-4E-BP1 expression correlated with cytoplasmic p-ERK
expression in the report of Korkolopoulou et al. [30],
consistent with in vitro data indicating the emerging role
of ERK signaling in regulating 4E-BP1 [43]. Also, from
the latter report [30], a signiﬁcant correlation of p-4E-BP1
expression with nuclear p-AKT was denoted, which was in
accordance with the data of Ermoian et al. [36] that observed
a similar association; an important ﬁnding emerging from
these two reports is the absence of correlation between p-4E-
BP1 and p-S6 [36], from on one hand, and among p-4E-BP1
and p-p70S6K, on the other hand [30]. This ﬁnding shows
that, in the regulation and activation of these two molecules,
other pathways may be implicated; VEGF, which is a marker
of angiogenesis (see previous sections), was also found to be
correlated with p-4E-BP1 [30].
One of the most important ﬁndings emerging from the
investigation of Korkolopoulou et al. [30] is the independent
adverse prognostic signiﬁcance of p-4E-BP1 expression, in
the entire cohort and glioblastomas, which has not been
documented thus far. In vitro experiments have documented
sensitization of U87 glioblastoma xenografts to irradia-
tion following 4E-BP1 targeting and decreased hypoxia
tolerance, indicating that glioblastomas, which are known
to be hypoxic, are expected to rely more on translation
regulation pathways for critical functions than their lower
grade counterparts [44] thus corroborating the ﬁnding of
Korkolopoulou et al. [30] that the prognostic eﬀect of 4E-
BP1 was established in glioblastomas.
2.6. Therapeutic Targeting of AKT-mTOR Pathway in Astro-
cytomas. The development of small kinase inhibitors has
improved clinical practice for several solid tumors and
presented a reasonable strategy for astrocytomas treatment.
P r i m a r yg l i o m ac e l lc u l t u r e sa sw e l la sU 8 7a n dU 2 5 1c e l l
lines where a strong activation of AKT/mTOR pathway was
observed exhibited increased sensitivity to rapamycin, the
archetypic mTOR inhibitor which did not, however, caused
a compensatory AKT activation resulting from mTORC1
negative feedback via insulin receptor substrate (IRS1,
Figure 1)[ 30, 45]. Additionally, rapamycin was eﬀective in
inhibiting the phosphorylation of both p70S6K and 4E-BP1
even at 48 hours [30] being a clinical promise in recurrent
glioblastomapatientsdisplaying higherlevelsofp-p70S6Kin
baseline tumor samples [46].
Unfortunately, single agent mTOR inhibitors such as
rapamycin (sirolimus, CCL-779) that speciﬁcally complexes
with FK506-binding protein 12 (FKBP12), thereby inter-
acting allosterically and inhibiting mTOR (Figure 1), has
produced minimal clinical activity and improvement in
neuroimaging of recurrent glioblastoma patients [47, 48].
The PFS6 (progression-free survival at 6 months) was rather
low at 7.8%, whereas the median OS was 4.4 months. Addi-
tional, the rapalogs, temsirolimus (CCI-779), deforolimus
(AP23573), and everolimus (RAD001) have also been gener-
ated without major clinical beneﬁt, and, although they are all
well tolerated, some toxicities have been reported including
lymphopenia, hyperlipidemia, stomatitis, and increased risk
of opportunistic infections [46, 48, 49]. Furthermore, a
rapamycin phase I trial was conducted in recurrent glioma
patients deﬁcient in PTEN based on preclinical data where
PTEN mutant/null tumors exhibited an enhanced suscepti-
bility to mTOR inhibition [50–52]. Interestingly, a complete
inhibitionofproliferationwasobservedinhalfofthepatients
which correlated to mTORC1 inhibition.
Taking into account the complexity of intracellular signal
transduction pathways and the ability of tumor cells to
compensate for acute changes, it is not surprising that
single-agent therapies have a limited eﬃcacy against most
solid tumors, including gliomas [45]. The possibility of an
upstream positive feedback loop at the PI3K level has driven
therapeutic targeting towards multiple signaling molecules
of the EGFR-PI3K-mTOR axis and identiﬁcation of agents
showing additive or synergistic antitumor eﬀects [28].
Indeed, preclinical studies of combined EGFR and mTOR
inhibitors have shown antiproliferative and proapoptotic
eﬀects against gliomas [45, 53]. In accordance, several pilot
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either a promising PFS6 at 25% for glioblastoma patients
[54] or disease stabilization [55].
Initial phase I studies indicated that combination treat-
ment in recurrent glioblastoma patients was well tolerated
resulting either in stabilization of the disease for some
patients or partial response rates [54, 56]. However, in a
more recent phase I and II study of recurrent glioblastoma,
combined treatment use of erlotinib and temsirolimus
caused increased toxicity without major clinical advantages.
Temsirolimus was maximally tolerated at 15mg per week
(lower dose than used in monotherapy) and erlotinib
at 150mg per day. Most common grade 3 toxicity was
rash followed by severe mucositis, thrombocytopenia, and
diarrhea. On phase II trial, PFS6 of 40 glioblastoma patients
was 12.5% with the median PFS being 8 weeks and only 30%
of patients exhibiting stable disease. Trials involving combi-
nations of cytotoxic drugs with mTOR inhibitors have been
initiatedrecentlyaiminginreducingtheimmunosuppressive
consequences.
Several factors may contribute to this minimal antitumor
response to combination therapy of EGFR and mTOR
inhibitors in glioblastomas, including mainly therapy resis-
tance or use of inadequate drug doses [57]. It is evident
that glioblastomas exhibit molecular heterogeneity involving
EGFRvIII and PTEN mutations, increased AKT activation,
or MGMT promoter methylation that may diﬀerentiate the
eﬃciency of EGFR-AKT-mTOR cascade targeting among
patients. Although several studies have been performed
aiming to establish molecular proﬁles that would predict
predictive clinical responses towards EGFR and/or mTOR
inhibition, a convincing molecular signature for glioblas-
toma is still elusive. Additional to identiﬁcation of driver
mutations as therapeutic targets, eﬃcient target inhibition
is also important. The use of rapamycin and its derivatives
as potent mTOR inhibitors at the current clinical doses
has been challenged recently, especially regarding inhibition
of 4E-BP1 and proliferation in some patients [58]. A
better activity towards this pathway is expected from next
generation mTOR inhibitors [58, 59].It hasbeen arguedthat
modulation of 4E-BP1 function may serve to determine the
sensitivity of tumor cells to PI3K/AKT pathway inhibitors. It
is thus conceivablethat 4E-BP1 modulation may have a place
inthetreatmentoptionsforglioblastomaasanadjuncttothe
existing or upcoming cytotoxic therapies.
3. Conclusion
It is evident that AKT-mTOR pathway activation is highly
implicated in glioma biology contributing to tumor pro-
gression and angiogenesis. Many reports, however, analyzing
the same molecule in gliomas had often controversial or
discrepant ﬁndings, preventing us to generate reliable con-
clusions regarding the clinical and prognostic importance
of these molecules in astrocytomas. This discrepancy could
be attributed to diﬀerences in techniques used, antibodies,
cohorts, and so forth. What was missing from most reports
cited in this paper was the validation of their ﬁndings. For
example, in the study of Korkolopoulou et al. [30], the
IHC was validated by WB and by Rapamycin treatment,
whereas McBride et al. [35]u s e dt w od i ﬀerent antibodies
for the same protein (p-S6), which served as an internal
validation for their IHC. On the other hand, Pelloski et al.
[22] validated the ﬁndings of their IHC by using a validation
cohort diﬀerentfromtheirmaincohortenrolledinthestudy.
Despite these remarks, the implication of activated AKT-
mTOR pathway in the pathogenesis of human astrocytomas
could not be ignored. Some ﬁndings of the cited reports
were similar and allowed us to generate a safe conclusion.
For example, activated AKT was seen to correlatewith tumor
grade in all cited reports except one. More studies are needed
inordertovalidatetheﬁndingsofthecitedreports,especially
for mTOR and the eﬀectors 4E-BP1 and p70S6K.
Furthermore, the AKT-mTOR pathway remains a prom-
ising and potential target for glioblastoma therapy. Due
to the molecular heterogeneity of glioblastomas, it is evi-
dent that strategies targeting this pathway require consid-
erable advances in genetics and pharmacology. Genomic
approaches of large scale are required for identiﬁcation of
main driver mutations and establishment of molecular sig-
natures leading to successful application of mTOR-targeted
therapy.Screeningtumorsamplesforcompensatoryreceptor
tyrosine kinases will identify those patients that require
combinations of multiple kinase inhibitors for successful
downstream signaling suppression [60]. The recent cate-
gorization of glioblastoma subtypes is an important tool
in identifying tumors that are more susceptible to mTOR
targeting [61].
Radiotherapy in combination with mTOR inhibition
(temsirolimus) is an alternative schedule that has proved
eﬃcient in preclinical studies [62] and is currently under
evaluation in a clinical study of newly diagnosed glioblas-
tomas in comparison to chemoirradiation and lack of
MGMT methylation [63].
Finally, advances in pharmacological approaches have
resulted in production of novel mTOR inhibitors with an
expected superior activity than rapalogs [59, 64]. Interesting
clinical data are expected from a current phase I trial
where combination of mTORC1 and 2 inhibitors as well as
combinationofmTORC1and2andPI3Kinhibitorshasbeen
applied to patients with glioblastomas that have undergone
radiation therapy.
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